The gastric H+,K+-ATPase: the site of action of omeprazole
- PMID: 2557669
The gastric H+,K+-ATPase: the site of action of omeprazole
Abstract
The mammalian parietal cell is dedicated to the secretion of HCl in response to various stimuli and second messengers. Oxidative metabolism in the cell increases about 10-fold in order to supply ATP to the gastric proton pump, the H+,K+-ATPase. This pump appears to be present only in the parietal cell. This membrane-embedded enzyme uses the scalar energy of ATP hydrolysis to carry out the vectorial transport of H+ in one direction in exchange for K+ in the other direction. In the cytoplasmic vesicle, K+ does not permeate the membrane, whereas in the secretory canaliculus, there is a Cl- channel and a KCl cotransport pathway which allow K+ and Cl- to exit from the cell. The K+ is then recycled back into the cell by the ATPase, and H+ secretion occurs into the canalicular space. Although there are other proton pumps, only the gastric H+,K+-ATPase has this exchange mechanism and only the gastric H+,K+-ATPase is able to generate a pH of less than 4. Thus the gastric proton pump has a unique structure and mechanism, and produces a unique luminal pH. This enzyme is therefore an appropriate target for rational drug design.
Similar articles
-
Biological basis of omeprazole therapy.J Gastroenterol Hepatol. 1989;4 Suppl 2:7-18. J Gastroenterol Hepatol. 1989. PMID: 2562365 Review.
-
Omeprazole: mode of action and effect on acid secretion in animals.Methods Find Exp Clin Pharmacol. 1989;11 Suppl 1:101-6. Methods Find Exp Clin Pharmacol. 1989. PMID: 2657278 Review.
-
The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.Scand J Gastroenterol Suppl. 1985;108:37-51. Scand J Gastroenterol Suppl. 1985. PMID: 2988109
-
[Inhibition of H+/K+-ATPase in the parietal cell with omeprazole: a new principle of gastric acid inhibition].Ned Tijdschr Geneeskd. 1985 Apr 13;129(15):679-82. Ned Tijdschr Geneeskd. 1985. PMID: 2986019 Review. Dutch. No abstract available.
-
Mechanisms of gastric proton pump inhibition by calcium channel antagonists.J Pharmacol Exp Ther. 1990 Mar;252(3):1102-7. J Pharmacol Exp Ther. 1990. PMID: 2156990
Cited by
-
Clinical pharmacology of omeprazole.Clin Pharmacokinet. 1991 Jan;20(1):38-49. doi: 10.2165/00003088-199120010-00003. Clin Pharmacokinet. 1991. PMID: 2029801 Review.
-
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br J Clin Pharmacol. 2001 Oct;52(4):349-55. doi: 10.1046/j.0306-5251.2001.01499.x. Br J Clin Pharmacol. 2001. PMID: 11678778 Free PMC article. Review.
-
Progress with proton pump inhibition.Yale J Biol Med. 1992 Nov-Dec;65(6):649-57;discussion 689-92. Yale J Biol Med. 1992. PMID: 1341069 Free PMC article. Review.
-
Chronic omeprazole treatment increases duodenal susceptibility to ethanol injury in rats.Dig Dis Sci. 1991 Jul;36(7):897-904. doi: 10.1007/BF01297138. Dig Dis Sci. 1991. PMID: 2070702
-
Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.Dig Dis Sci. 1996 Oct;41(10):2039-47. doi: 10.1007/BF02093608. Dig Dis Sci. 1996. PMID: 8888719
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources